News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Odyssey Thera, Inc. Initiates Project With F. Hoffmann-La Roche Ltd. (RHHBY)

10/19/2005 5:10:50 PM

SAN RAMON, Calif., April 8 /PRNewswire/ -- Odyssey Thera, Inc. announced today an agreement with F. Hoffmann-La Roche Ltd, to carry out pilot studies aimed at profiling selected Roche compounds across Odyssey Thera, Inc.'s panels of cell-based assays in order to further characterize mechanism of action and pathway activity.

Odyssey Thera, Inc. (Odyssey Thera) probes the intricate biochemical networks of living cells to identify on-pathway and off-pathway effects of drugs and lead compounds. The company has validated this approach in its KUDOS program, which analyzed the mechanism of action of 100 known drugs in real time in human cells. KUDOS (Known and Unknown Drug Optimization Strategy) revealed previously undocumented mechanisms of action, as well as potential new therapeutic utility, for several known drugs. Drugs that are more selective can be distinguished from those that are less selective.

"Our goal is to identify and eliminate unanticipated activity much earlier in the drug discovery process, before significant resources are invested in pre-clinical and clinical development," says Dr. John Westwick, Chief Scientific Officer of Odyssey Thera. Financial terms of the agreement were not disclosed. F. Hoffmann-La Roche Ltd is the fourth pharmaceutical firm to initiate a project with Odyssey Thera in the last six months.

About Odyssey Thera

Odyssey Thera, Inc. is a privately held biotechnology company that utilizes a pathway-based approach to drug discovery in order to greatly improve the effectiveness and productivity of the drug development process and to identify new indications for existing drugs. With an initial focus on anti-cancer agents, Odyssey Thera uses its proprietary protein-fragment complementation assay (PCA) process and high throughput systems biology to improve the quality of information available about targets and lead compounds early in drug discovery and development. PCA combined with the use of living human cells instead of isolated proteins strengthens the predictive value of preclinical screening, significantly reducing the number of failures in drug discovery and improving pipelines and treatments for cancer and other diseases. For more information, please visit the company website at

Odyssey Thera, Inc.

CONTACT: Marnie L. MacDonald, Ph.D., President and CEO of Odyssey Thera,Inc., +1-925-242-5001

Read at

Related News

comments powered by Disqus